Close
  • Latest News
  • Big Data and Analytics
  • Cloud
  • Networking
  • Cybersecurity
  • Applications
  • IT Management
  • Storage
  • Sponsored
  • Mobile
  • Small Business
  • Development
  • Database
  • Servers
  • Android
  • Apple
  • Innovation
  • Blogs
  • PC Hardware
  • Reviews
  • Search Engines
  • Virtualization
Read Down
Sign in
Close
Welcome!Log into your account
Forgot your password?
Read Down
Password recovery
Recover your password
Close
Search
Logo
Logo
  • Latest News
  • Big Data and Analytics
  • Cloud
  • Networking
  • Cybersecurity
  • Applications
  • IT Management
  • Storage
  • Sponsored
  • Mobile
  • Small Business
  • Development
  • Database
  • Servers
  • Android
  • Apple
  • Innovation
  • Blogs
  • PC Hardware
  • Reviews
  • Search Engines
  • Virtualization
More
    Home Innovation
    • Innovation

    IBM Assists in Creation of New Breast Cancer Drug Delivery System

    By
    Darryl K. Taft
    -
    November 3, 2013
    Share
    Facebook
    Twitter
    Linkedin

      IBM announced that its researchers have been instrumental in the creation of a new drug delivery mechanism to fight breast cancer.

      Scientists from IBM and Singapore’s Institute of Bioengineering and Nanotechnology (IBN) published a breakthrough drug-delivery technique, demonstrating the first biodegradable, biocompatible and non-toxic hydrogel that can deliver treatment more efficiently to people fighting breast cancer.

      According to IBM, around one-quarter of all breast cancer patients have human epidermal growth factor receptor 2 (HER2), a specific type of cancerous cell identified in this study that is considered aggressive because it spreads quickly and has a low survival rate. Treatment of breast cancer varies according to the size, stage and rate of growth, as well as the type of tumor. There are currently three main categories of post-surgery therapies available: hormone blocking therapy, chemotherapy and monoclonal antibodies (mAbs) therapy.

      In the case of antibodies, the drugs are paired with saline and delivered intravenously into the body. Targeting specific cells or proteins, the antibodies block specific cell receptors to destroy cancer cells and suppress tumor growth. However, these drugs are absorbed in the body and have limited lifetimes and effectiveness when injected directly into the bloodstream.

      Recognizing this, IBM and IBN scientists developed a novel synthetic hydrogel made up of more than 96 percent water and a degradable polymer that is capable of sequestering a range of cargos from small molecules to large molecules including mAbs.

      It also exhibits many of the biocompatible characteristics of water-soluble polymers, which hold form in the body without completely dissolving. This allows the hydrogel to function as a depot for the drug to slow-release its contents in a targeted location directly at the tumor site over weeks instead of days. Once the drug has been delivered, the hydrogel biodegrades naturally and passes through the body.

      The IBM nanomedicine polymer program–which started in IBM’s Research labs four years ago with the mission to improve human health–stems from decades of materials development traditionally used for semiconductor technologies.

      “Drawing from our experience in materials innovation for electronics technology, we are now applying these techniques to the quest for improved health,” said Dr. James Hedrick, an advanced organic materials scientist at IBM’s Almaden research center in San Jose, Calif., in a statement. “This hydrogel can help deliver drugs over an extended period of time without causing a significant immune response, effectively sending its contents directly to the tumor without harming healthy surrounding cells.”

      In animal studies done by Singapore’s IBN, testing demonstrated improved results–including shrinking tumors, patient weight gain and the need for fewer treatments–when the antibody was paired and delivered with the hydrogel, even at low concentration, than on its own.

      Big Blue said IBN testing showed that over the course of 28 days, a tumor shrank 77 percent when paired with the hydrogel via subcutaneous injection at the tumor site. Also, when paired with the hydrogel and injected subcutaneously at a site far away from the tumor, the treatment frequency was reduced from four to one while maintaining a similar therapeutic effect. This is when compared to just the antibody solution formulation injected intravenously.

      Moreover, the ability to target and deliver the drug directly at the tumor site allowed for only the infected cells to be eradicated, leaving healthy cells alone. This resulted in stable to moderate weight gain during the study instead of massive weight loss traditionally associated with cancer drug treatments. And since the hydrogel is non-toxic, it demonstrated high biocompatibility as evidenced by no cellular inflammation with minimal immune system response while degrading naturally and passing through the body within six weeks, IBM officials said.

      “We have developed new, effective materials for nanomedicine, which has been one of IBN’s key research focus areas since 2003,” said Dr. Yi Yan Yang, group leader for nanomedicine at Singapore’s IBN, in a statement. “The sustained delivery of Herceptin from our hydrogel provides greater anti-tumor efficacy and reduces injection frequency. Thus, our approach may help to improve patient compliance, offering a better alternative to existing breast cancer treatments. This technology can also be used to deliver other types of antibodies or proteins to treat different diseases.”

      Darryl K. Taft
      Darryl K. Taft covers the development tools and developer-related issues beat from his office in Baltimore. He has more than 10 years of experience in the business and is always looking for the next scoop. Taft is a member of the Association for Computing Machinery (ACM) and was named 'one of the most active middleware reporters in the world' by The Middleware Co. He also has his own card in the 'Who's Who in Enterprise Java' deck.

      MOST POPULAR ARTICLES

      Big Data and Analytics

      Alteryx’s Suresh Vittal on the Democratization of...

      James Maguire - May 31, 2022 0
      I spoke with Suresh Vittal, Chief Product Officer at Alteryx, about the industry mega-shift toward making data analytics tools accessible to a company’s complete...
      Read more
      Cybersecurity

      Visa’s Michael Jabbara on Cybersecurity and Digital...

      James Maguire - May 17, 2022 0
      I spoke with Michael Jabbara, VP and Global Head of Fraud Services at Visa, about the cybersecurity technology used to ensure the safe transfer...
      Read more
      Cloud

      IGEL CEO Jed Ayres on Edge and...

      James Maguire - June 14, 2022 0
      I spoke with Jed Ayres, CEO of IGEL, about the endpoint sector, and an open source OS for the cloud; we also spoke about...
      Read more
      Applications

      Cisco’s Thimaya Subaiya on Customer Experience in...

      James Maguire - May 10, 2022 0
      I spoke with Thimaya Subaiya, SVP and GM of Global Customer Experience at Cisco, about the factors that create good customer experience – and...
      Read more
      Big Data and Analytics

      GoodData CEO Roman Stanek on Business Intelligence...

      James Maguire - May 4, 2022 0
      I spoke with Roman Stanek, CEO of GoodData, about business intelligence, data as a service, and the frustration that many executives have with data...
      Read more
      Logo

      eWeek has the latest technology news and analysis, buying guides, and product reviews for IT professionals and technology buyers. The site’s focus is on innovative solutions and covering in-depth technical content. eWeek stays on the cutting edge of technology news and IT trends through interviews and expert analysis. Gain insight from top innovators and thought leaders in the fields of IT, business, enterprise software, startups, and more.

      Facebook
      Linkedin
      RSS
      Twitter
      Youtube

      Advertisers

      Advertise with TechnologyAdvice on eWeek and our other IT-focused platforms.

      Advertise with Us

      Menu

      • About eWeek
      • Subscribe to our Newsletter
      • Latest News

      Our Brands

      • Privacy Policy
      • Terms
      • About
      • Contact
      • Advertise
      • Sitemap
      • California – Do Not Sell My Information

      Property of TechnologyAdvice.
      © 2022 TechnologyAdvice. All Rights Reserved

      Advertiser Disclosure: Some of the products that appear on this site are from companies from which TechnologyAdvice receives compensation. This compensation may impact how and where products appear on this site including, for example, the order in which they appear. TechnologyAdvice does not include all companies or all types of products available in the marketplace.

      ×